Side-by-side · Research reference

CardiogenvsPT-141

Side-by-side comparison across mechanism, dosage, evidence, side effects, administration, and stack synergies. Citations on every claim where available.

AAnimal-MechanisticHUMAN-REVIEWED5/46 cited

BFDA-ApprovedHUMAN-REVIEWED13/41 cited

Cardiogen

Bioregulator · Cardiac

CardiacTissue target

Gene regulationMechanism

AnimalEvidence level

SQ · Variable protocols

PT-141

MC4R Agonist · FDA-Approved (HSDD)

1.75 mgPer doseVYLEESI (bremelanotide injecti 2019

Pre-sexTimingVYLEESI (bremelanotide injecti 2019

~2.7 hrHalf-lifeVYLEESI (bremelanotide injecti 2019

SQ · Abdomen / thigh · ≥45 min before sex

01Mechanism of Action

Parameter

Cardiogen

PT-141

Primary target

Cardiovascular cell gene expressionKhavinson 2022

Melanocortin-4 receptor (MC4R) in hypothalamusSimerly 2023 VYLEESI (bremelanotide injecti 2019

Pathway

Peptide bioregulation → modulation of SASP / inflammaging → cardiac tissue homeostasisKhavinson 2022

MC4R agonism in paraventricular nucleus → autonomic + neuroendocrine sexual arousal pathwaysSimerly 2023

Downstream effect

Suppression of senescence-associated secretory phenotype (SASP), reduction of age-related inflammatory markers, modulation of heat shock protein expression in cardiac tissue

Increased sexual desire and arousal; central rather than peripheral mechanismClayton 2015

Feedback intact?

Presumed — peptide bioregulators act via gene regulation, not receptor agonism

—

Origin

Derived from cardiac tissue peptide extracts; synthetic analogue based on Khavinson bioregulator methodology

Cyclic 7-AA peptide derived from α-MSH (agonist Ac-Nle-Asp-His-D-Phe-Arg-Trp-Lys-OH cyclic)VYLEESI (bremelanotide injecti 2019

Antibody development

—

02Dosage Protocols

Parameter

Cardiogen

PT-141

Standard dose

Variable — typically 10–20 mg per course

No standardised human protocol; animal-derived dosing.

1.75 mg SQVYLEESI (bremelanotide injecti 2019

Single dose ≥45 min before anticipated sexual activity. Max 1 dose / 24 hr.

Frequency

Intermittent courses — 10–20 days, repeated periodically

Khavinson-school bioregulators typically dosed as periodic interventions, not continuous.

PRN, max 8 doses / month

Evidence basis

Animal models / mechanistic studies

No Phase 1+ human trials in PubMed.

FDA-approved (HSDD pre-menopausal women)VYLEESI (bremelanotide injecti 2019 Clayton 2015

Route

Subcutaneous injection

—

Duration

10–20 day courses, repeated 2–4× per year

Russian geriatric protocols; unclear extrapolation to general populations.

PRN; reassess if no benefit after 8 doses

Lower / starter dose

—

1 mg (off-label)

Reconstitution

—

Pre-filled commercial pen (Vyleesi). Research vial: bacteriostatic water.

Timing

—

≥45 min before sexual activity

Half-life

—

~2.7 hrVYLEESI (bremelanotide injecti 2019

04Side Effects & Safety

Parameter

Cardiogen

PT-141

Injection site reactions

Mild erythema, induration (presumed)

—

Systemic adverse events

No documented serious AEs in available literature

Very limited safety data; no rigorous pharmacovigilance.

—

Immunogenicity

Unknown — no antibody development studies published

—

Long-term safety

Unknown — no extended human trials indexed in PubMed

—

Nausea

—

Common (~40%); often transientVYLEESI (bremelanotide injecti 2019

Flushing

—

Common, transient

Injection site reaction

—

Erythema, mild pain

Headache

—

Common

Hyperpigmentation (focal)

—

Rare focal skin darkening; reversible after discontinuationVYLEESI (bremelanotide injecti 2019

Hypertension (transient)

—

Mean ↑6 mmHg systolic peaking ~4 h post-dose; resolves within 12 hVYLEESI (bremelanotide injecti 2019

Pregnancy / OB

—

Contraindicated

Cardiovascular disease

—

Use caution; transient BP rise

Absolute Contraindications

Cardiogen

·Active malignancy (theoretical peptide growth factor concern)
·Hypersensitivity to peptide components

PT-141

·Uncontrolled hypertension
·Known cardiovascular disease (caution)
·Pregnancy

Relative Contraindications

Cardiogen

·Acute cardiac events (no safety data in acute MI, unstable angina)
·Pregnancy / lactation (no reproductive toxicity data)

PT-141

·Pre-existing hyperpigmentation disorders
·MC4R-pathway-dependent psychiatric conditions

05Administration Protocol

Parameter

Cardiogen

PT-141

1. Reconstitution

Add sterile water or saline per manufacturer instructions (typically 1–2 mL per lyophilised vial). Roll gently to dissolve.

Vyleesi: pre-filled auto-injector. Research vial: 2 mL bacteriostatic water per 10 mg → 5 mg/mL.

2. Injection site

Subcutaneous — abdomen or thigh. Rotate sites. Use sterile technique.

SQ — abdomen or thigh.

3. Timing

Variable — often evening injection. No established circadian preference.

≥45 min before sexual activity for peak effect. Effect persists ~6–8 h.

4. Storage

Lyophilised: refrigerate 2–8 °C, protect from light. Reconstituted: use immediately or refrigerate, discard after 7–14 days per labeling.

Vyleesi: room temp ≤30 °C. Research vial: refrigerate after reconstitution.

5. Needle

27–30G insulin syringe, 45° angle for subcutaneous administration.

Auto-injector (Vyleesi) or 29–31G, 4–8 mm insulin syringe.

06Stack Synergy

Cardiogen

+ Thymalin

Moderate

View Thymalin →

Khavinson-school multi-organ bioregulator approach: thymalin (thymic peptide) addresses immune senescence while cardiogen targets cardiac tissue. Combined use in geriatric populations demonstrated normalisation of cardiovascular, endocrine, and immune parameters with reduced mortality over 6–8 years of observation.

Cardiogen: 10–20 mg SQ · 10–20 day course
Thymalin: 10–30 mg IM · concurrent or sequential courses
Frequency: 2–4 courses per year
Primary benefit: Multi-system aging mitigation, cardiovascular and immune homeostasis

PT-141

— no documented stacks